Interestingly, the combination of BCL-2 and MCL-1 inhibitors has been shown to be selectively toxic melanoma24,25,41,42, acute myeloid leukemia43, and cervical cancer cells22,23, but mechanisms for this synergy remain elusive. This evidence concerns the gene BCL2 and cervical carcinoma.